Shanghai Shyndec to expand business, elect new board in December meeting

Shanghai Shyndec Pharmaceutical Co., Ltd. (CSPCG Modern) is scheduled to hold its third extraordinary general meeting of shareholders for 2025 on December 24, 2025, at 10:00 AM, at its Shanghai headquarters. The meeting will address significant changes to the company's business scope, amendments to its articles of association, and revisions to its external guarantee management system. Proposed additions to the business scope include food production and sales, internet medical e-commerce, and cosmetics production.

Shareholders will also vote on the election of the ninth board of directors. Proposals include the election of non-independent directors Xu Jihui, Cai Miasong, Liu Yong, Xing Yonggang, and Zhu Lin, and independent directors Wu Fanhong, Chu Wengong, and Shao Ruiqing, all for a three-year term. These changes reflect the company's strategic adjustments.

The meeting will also review a proposal to revise the company's external guarantee management system, notably introducing a requirement for controlling shareholders, actual controllers, and their related parties to provide counter-guarantees when the company provides guarantees for them. Furthermore, the revised policy clarifies that guarantees by subsidiaries are treated as guarantees by CSPCG Modern, requiring board or shareholder approval.